Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Mar;31(3):323–332. doi: 10.1111/j.1365-2125.1991.tb05536.x

Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.

D L Murdoch 1, G D Thomson 1, G G Thompson 1, G D Murray 1, M J Brodie 1, G T McInnes 1
PMCID: PMC1368359  PMID: 2054272

Abstract

1. Potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol were evaluated in two double-blind, randomised, balanced, crossover studies employing the same six healthy males. 2. The first study examined the effect of repeated propranolol administration on the pharmacodynamics and pharmacokinetics of verapamil after single oral and intravenous doses. The second explored the pharmacodynamics and pharmacokinetics of verapamil and propranolol alone and in combination after single and repeated oral doses. 3. The magnitude of the prolongation of PR interval induced by oral and intravenous verapamil was not affected by pre-treatment with propranolol. When verapamil and propranolol were co-administered as single doses, effects on PR interval were additive but, following repeated doses, a trend towards greater than additive prolongation was seen. The arithmetic sum of the effects of the two drugs was 23% (95% C.I. 8-38%) but the measured increase after the combination was 40% (95% C.I. 26-54%). 4. The extent of reduction in heart rate and blood pressure at rest and after exercise following repeated doses of propranolol was not influenced by single oral or intravenous doses of verapamil. The heart rate and blood pressure responses to single and repeated oral doses of verapamil and propranolol in combination were significantly greater than those after either drug alone and approximated to the arithmetic sum of the individual responses. 5. Although repeated administration of propranolol reduced hepatic blood flow as assessed by indocyanine green clearance, there was no evidence of an interaction between the drugs at this level. 6. The pharmacokinetics of verapamil and norverapamil were not significantly affected by prior propranolol. After single doses of verapamil and propranolol in combination, the maximum plasma concentration of propranolol was increased and the oral clearance of verapamil reduced. No pharmacokinetic interaction was observed after repeated doses. 7. These findings provide little evidence of a pharmacodynamic or pharmacokinetic interaction between verapamil and propranolol in normal subjects. Most of the haemodynamic responses to these drugs in combination can be explained by additive drug effects but an interaction affecting AV conduction after repeated doses cannot be excluded. The minor pharmacokinetic interaction between the drugs is unlikely to be relevant to the pharmacodynamic changes.

Full text

PDF
323

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abernethy D. R., Schwartz J. B., Todd E. L., Luchi R., Snow E. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. Ann Intern Med. 1986 Sep;105(3):329–336. doi: 10.7326/0003-4819-105-3-329. [DOI] [PubMed] [Google Scholar]
  2. Anderson P., Bondesson U., de Faire U. Pharmacokinetics of verapamil in patients with hypertension. Eur J Clin Pharmacol. 1986;31(2):155–163. doi: 10.1007/BF00606652. [DOI] [PubMed] [Google Scholar]
  3. Bassan M., Weiler-Ravell D., Shalev O. Additive antianginal effect of verapamil in patients receiving propranolol. Br Med J (Clin Res Ed) 1982 Apr 10;284(6322):1067–1070. doi: 10.1136/bmj.284.6322.1067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bax N. D., Tucker G. T., Lennard M. S., Woods H. F. The impairment of lignocaine clearance by propranolol--major contribution from enzyme inhibition. Br J Clin Pharmacol. 1985 May;19(5):597–603. doi: 10.1111/j.1365-2125.1985.tb02686.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Benaim M. E. Asystole after verapamil. Br Med J. 1972 Apr 15;2(5806):169–170. doi: 10.1136/bmj.2.5806.169-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med. 1982 Dec 23;307(26):1618–1627. doi: 10.1056/NEJM198212233072605. [DOI] [PubMed] [Google Scholar]
  7. CAESAR J., SHALDON S., CHIANDUSSI L., GUEVARA L., SHERLOCK S. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci. 1961 Aug;21:43–57. [PubMed] [Google Scholar]
  8. Carruthers S. G., McCall B., Cordell B. A., Wu R. Relationships between heart rate and PR interval during physiological and pharmacological interventions. Br J Clin Pharmacol. 1987 Mar;23(3):259–265. doi: 10.1111/j.1365-2125.1987.tb03043.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dauchot P., Gravenstein J. S. Effects of atropine on the electrocardiogram in different age groups. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):274–280. doi: 10.1002/cpt1971122part1274. [DOI] [PubMed] [Google Scholar]
  10. Dominic J., McAllister R. G., Jr, Kuo C. S., Reddy C. P., Surawicz B. Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clin Pharmacol Ther. 1979 Dec;26(6):710–714. doi: 10.1002/cpt1979266710. [DOI] [PubMed] [Google Scholar]
  11. Echizen H., Vogelgesang B., Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther. 1985 Jul;38(1):71–76. doi: 10.1038/clpt.1985.137. [DOI] [PubMed] [Google Scholar]
  12. Eichelbaum M., Ende M., Remberg G., Schomerus M., Dengler H. J. The metabolism of DL-[14C]verapamil in man. Drug Metab Dispos. 1979 May-Jun;7(3):145–148. [PubMed] [Google Scholar]
  13. Eichelbaum M., Mikus G., Vogelgesang B. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br J Clin Pharmacol. 1984 Apr;17(4):453–458. doi: 10.1111/j.1365-2125.1984.tb02371.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Evans G. H., Shand D. G. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):487–493. doi: 10.1002/cpt1973144part1487. [DOI] [PubMed] [Google Scholar]
  15. Feldman R. D., Park G. D., Lai C. Y. The interaction of verapamil and norverapamil with beta-adrenergic receptors. Circulation. 1985 Sep;72(3):547–554. doi: 10.1161/01.cir.72.3.547. [DOI] [PubMed] [Google Scholar]
  16. Findlay I. N., MacLeod K., Gillen G., Elliott A. T., Aitchison T., Dargie H. J. A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris. Br Heart J. 1987 Apr;57(4):336–343. doi: 10.1136/hrt.57.4.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Halperin A. K., Gross K. M., Rogers J. F., Cubeddu L. X. Verapamil and propranolol in essential hypertension. Clin Pharmacol Ther. 1984 Dec;36(6):750–758. doi: 10.1038/clpt.1984.253. [DOI] [PubMed] [Google Scholar]
  18. Hamann S. R., Kaltenborn K. E., Vore M., Tan T. G., McAllister R. G., Jr Cardiovascular and pharmacokinetic consequences of combined administration of verapamil and propranolol in dogs. Am J Cardiol. 1985 Jul 1;56(1):147–156. doi: 10.1016/0002-9149(85)90584-3. [DOI] [PubMed] [Google Scholar]
  19. Harapat S. R., Kates R. E. High-performance liquid chromatographic analysis of verapamil. II. Simultaneous quantitation of verapamil and its active metabolite, norverapamil. J Chromatogr. 1980 Mar 14;181(3-4):484–489. [PubMed] [Google Scholar]
  20. Johnston A., Burgess C. D., Hamer J. Systemic availability of oral verapamil and effect on PR interval in man. Br J Clin Pharmacol. 1981 Sep;12(3):397–400. doi: 10.1111/j.1365-2125.1981.tb01233.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Johnston D. L., Gebhardt V. A., Donald A., Kostuk W. J. Comparative effects of propranolol and verapamil alone and in combination on left ventricular function and volumes in patients with chronic exertional angina: a double-blind, placebo-controlled, randomized, crossover study with radionuclide ventriculography. Circulation. 1983 Dec;68(6):1280–1289. doi: 10.1161/01.cir.68.6.1280. [DOI] [PubMed] [Google Scholar]
  22. Keech A. C., Harper R. W., Harrison P. M., Pitt A., McLean A. J. Pharmacokinetic interaction between oral metoprolol and verapamil for angina pectoris. Am J Cardiol. 1986 Sep 1;58(6):551–552. doi: 10.1016/0002-9149(86)90032-9. [DOI] [PubMed] [Google Scholar]
  23. Kohlhardt M., Mnich Z. Studies on the inhibitory effect of verapamil on the slow inward current in mammalian ventricular myocardium. J Mol Cell Cardiol. 1978 Nov;10(11):1037–1052. doi: 10.1016/0022-2828(78)90400-5. [DOI] [PubMed] [Google Scholar]
  24. Leon M. B., Rosing D. R., Bonow R. O., Lipson L. C., Epstein S. E. Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol. 1981 Jul;48(1):131–139. doi: 10.1016/0002-9149(81)90582-8. [DOI] [PubMed] [Google Scholar]
  25. Macphee G. J., McInnes G. T., Thompson G. G., Brodie M. J. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet. 1986 Mar 29;1(8483):700–703. doi: 10.1016/s0140-6736(86)91099-8. [DOI] [PubMed] [Google Scholar]
  26. McCourty J. C., Silas J. H., Tucker G. T., Lennard M. S. The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. Br J Clin Pharmacol. 1988 Mar;25(3):349–357. doi: 10.1111/j.1365-2125.1988.tb03313.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. McInnes G. T., Brodie M. J. Drug interactions that matter. A critical reappraisal. Drugs. 1988 Jul;36(1):83–110. doi: 10.2165/00003495-198836010-00006. [DOI] [PubMed] [Google Scholar]
  28. McInnes G. T., Findlay I. N., Murray G., Cleland J. G., Dargie H. J. Cardiovascular responses to verapamil and propranolol in hypertensive patients. J Hypertens Suppl. 1985 Dec;3(3):S219–S221. [PubMed] [Google Scholar]
  29. McLean A. J., Knight R., Harrison P. M., Harper R. W. Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol. Am J Cardiol. 1985 Jun 1;55(13 Pt 1):1628–1629. doi: 10.1016/0002-9149(85)90987-7. [DOI] [PubMed] [Google Scholar]
  30. McLean A. J., McNamara P. J., duSouich P., Gibaldi M., Lalka D. Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther. 1978 Jul;24(1):5–10. doi: 10.1002/cpt19782415. [DOI] [PubMed] [Google Scholar]
  31. Meredith P. A., Elliott H. L., Pasanisi F., Kelman A. W., Sumner D. J., Reid J. L. Verapamil pharmacokinetics and apparent hepatic and renal blood flow. Br J Clin Pharmacol. 1985 Aug;20(2):101–106. doi: 10.1111/j.1365-2125.1985.tb05038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Milne J. R., Boothby C. B., Garrard C. S., Pickering D. Verapamil in cardiac arrhythmias. Br Med J. 1972 May 6;2(5809):348–349. doi: 10.1136/bmj.2.5809.348-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nayler W. G., McInnes I., Swann J. B., Price J. M., Carson V., Race D., Lowe T. E. Some effects of iproveratril (Isoptin) on the cardiovascular system. J Pharmacol Exp Ther. 1968 Jun;161(2):247–261. [PubMed] [Google Scholar]
  34. Packer M., Meller J., Medina N., Yushak M., Smith H., Holt J., Guererro J., Todd G. D., McAllister R. G., Jr, Gorlin R. Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation. 1982 Apr;65(4):660–668. doi: 10.1161/01.cir.65.4.660. [DOI] [PubMed] [Google Scholar]
  35. Price H. L., Cooperman L. H., Warden J. C. Control of the splanchnic circulation in man. Role of beta-adrenergic receptors. Circ Res. 1967 Sep;21(3):333–340. doi: 10.1161/01.res.21.3.333. [DOI] [PubMed] [Google Scholar]
  36. Reimann I. W., Klotz U., Siems B., Frölich J. Cimetidine increases steady state plasma levels of propranolol. Br J Clin Pharmacol. 1981 Dec;12(6):785–790. doi: 10.1111/j.1365-2125.1981.tb01307.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Reiter M. J., Shand D. G., Pritchett E. L. Comparison of intravenous and oral verapamil dosing. Clin Pharmacol Ther. 1982 Dec;32(6):711–720. doi: 10.1038/clpt.1982.227. [DOI] [PubMed] [Google Scholar]
  38. Routledge P. A., Shand D. G. Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979 Mar-Apr;4(2):73–90. doi: 10.2165/00003088-197904020-00001. [DOI] [PubMed] [Google Scholar]
  39. Singh B. N., Rebanal P., Piontek M., Nademanee K. Calcium antagonists and beta blockers in the control of mild to moderate systemic hypertension, with particular reference to verapamil and propranolol. Am J Cardiol. 1986 Feb 26;57(7):99D–105D. doi: 10.1016/0002-9149(86)90817-9. [DOI] [PubMed] [Google Scholar]
  40. Stern S., Eisenberg S. The effect of propranolol (Inderal) on the electrocardiogram of normal subjects. Am Heart J. 1969 Feb;77(2):192–195. doi: 10.1016/0002-8703(69)90350-0. [DOI] [PubMed] [Google Scholar]
  41. Subramanian B., Bowles M. J., Davies A. B., Raftery E. B. Combined therapy with verapamil and propranolol in chronic stable angina. Am J Cardiol. 1982 Jan;49(1):125–132. doi: 10.1016/0002-9149(82)90286-7. [DOI] [PubMed] [Google Scholar]
  42. Vestal R. E., Wood A. J., Shand D. G. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther. 1979 Aug;26(2):181–186. doi: 10.1002/cpt1979262181. [DOI] [PubMed] [Google Scholar]
  43. Vogelgesang B., Echizen H., Schmidt E., Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol. 1984 Nov;18(5):733–740. doi: 10.1111/j.1365-2125.1984.tb02536.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wagner J. G. Predictability of verapamil steady-state plasma levels from single-dose data explained. Clin Pharmacol Ther. 1984 Jul;36(1):1–4. doi: 10.1038/clpt.1984.129. [DOI] [PubMed] [Google Scholar]
  45. Warrington S. J., Holt D., Johnston A., Fitzsimons T. J. Pharmacokinetics and pharmacodynamics of verapamil in combination with atenolol, metoprolol and propranolol. Br J Clin Pharmacol. 1984;17 (Suppl 1):37S–44S. doi: 10.1111/j.1365-2125.1984.tb02426.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Westaby D., Bihari D. J., Gimson A. E., Crossley I. R., Williams R. Selective and non-selective beta receptor blockade in the reduction of portal pressure in patients with cirrhosis and portal hypertension. Gut. 1984 Feb;25(2):121–124. doi: 10.1136/gut.25.2.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wilkinson G. R., Shand D. G. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 Oct;18(4):377–390. doi: 10.1002/cpt1975184377. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES